Lisata Therapeutics, Inc. (LSTA) vs Pluri Inc. (PLUR)

Lisata Therapeutics, Inc. and Pluri Inc. are both Biotechnology companies. Lisata Therapeutics, Inc. and Pluri Inc. are of similar size ($13.5M and $13.0M). Pluri Inc. grew revenue faster over the last twelve months: −24.0% against −24.7%. Lisata Therapeutics, Inc. has the higher net margin (0.00% vs −2,344.6%) and the higher return on invested capital (0.00% vs −526.9%). Across the 17 metrics below, Lisata Therapeutics, Inc. leads on 9 and Pluri Inc. on 8.

Valuation

Metric LSTA PLUR Biotechnology median
P/E n/m n/m 7.88
P/S 0.95 10.07 11.47
P/B 1.80 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 0.28 30.14 10.73
Earnings yield (103.80%) (233.33%) (28.84%)
Free cash flow yield (85.85%) (197.46%) (23.03%)

Profitability

Metric LSTA PLUR Biotechnology median
Gross margin 0.49% 44.59% 65.16%
Operating margin 0.00% (2,454.53%) 0.00%
Net margin 0.00% (2,344.59%) 0.00%
Free cash flow margin 0.00% (1,988.48%) 0.00%
Return on equity (101.66%) 260.35% (57.72%)
Return on assets (80.81%) (74.95%) (49.22%)
Return on invested capital 0.00% (526.92%) 0.00%

Growth

Metric LSTA PLUR Biotechnology median
Revenue growth (TTM) (24.67%) (23.95%) 5.64%
EPS growth (last fiscal year) 20.42% 31.46% —
Revenue growth, 5-year CAGR (20.28%) 113.32% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LSTA PLUR Biotechnology median
Debt to equity 0.00 (1.62) 0.00
Current ratio 3.69 0.27 4.73
Net debt to EBITDA 0.88 (0.83) 0.96

Dividend

Metric LSTA PLUR Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric LSTA PLUR Biotechnology median
Market cap 13.52m 12.96m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack